Akèy › Kansè kolorektal › Ohio
Etid klinik pou Kansè kolorektal nan Ohio
63 etid pou Kansè kolorektal ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
- Cleveland24 etid
- Columbus24 etid
- Cincinnati21 etid
- Akron8 etid
- Toledo7 etid
- Dayton5 etid
- Youngstown5 etid
- Findlay4 etid
- Newark3 etid
Tèks ofisyèl etid la (Anglè)
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Miami Valley Hospital South, Centerville
- Ohio State University Comprehensive Cancer Center, Columbus
- Miami Valley Hospital, Dayton
- ak 4 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05673148A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Oncology Hematology Care - Blue Ash /ID# 280143, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07525206The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- ak 44 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Family Communications After Genetic Testing
- Aultman Alliance Community Hospital, Alliance
- Indu and Raj Soin Medical Center, Beavercreek
- Saint Elizabeth Boardman Hospital, Boardman
- ak 17 plis
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07143487A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #10, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 10, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05803382A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Oncology Hematology Care - Eastgate /ID# 271493, Cincinnati
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06820463Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Oncology Hematology Care - Eastgate, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- Oncology Hematology Care Clinical Trials, LLC, Fairfield
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07222800Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Gabrail Cancer Center, Canton
- University Hospital of Cleveland, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06750094A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Gabrail Cancer Center, Canton
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Cancer Center Fairview Hospital Moll Pavilion, Cleveland
- ak 8 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06662786Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Ohio State University Comprehensive Cancer Center, Columbus
- Saint Elizabeth Youngstown Hospital, Youngstown
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05863195A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07221357Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06102902Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- University of Cincinnati Medical Center, Cincinnati
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06445062Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Canton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07213609A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- University of Cincinnati Cancer Institute, Cincinnati
- Case Comprehensive Cancer Center, Cleveland
- Ohio State University-Arthur G James Comprehensive Cancer Center, Columbus
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07284849Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
- Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07044362Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05630794Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Akron
- Clinical Study Site, Canton
- Clinical Study Site, Cincinnati
- ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07228832A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- University of Cincinnati Cancer Center, Cincinnati
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07544589Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- University of Cincinnati (UC) - Cancer Institute, Cincinnati
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06586515FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06654037A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oncology Hematology Care Primary, Cincinnati
- Taylor Cancer Research Center, Maumee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT06948448A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
- Zangmeister Cancer Center, Columbus
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT06562543Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou Jul 6, 2026 · NCT06710756A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT07079631A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06051695Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.